Echavidre William, Fagret Daniel, Faraggi Marc, Picco Vincent, Montemagno Christopher
Biomedical Department, Centre Scientifique de Monaco, 98000 Monaco, Monaco.
Laboratory of Bioclinical Radiopharmaceutics, Universite Grenoble Alpes, CHU Grenoble Alpes, Inserm, 38000 Grenoble, France.
Cancers (Basel). 2023 Oct 3;15(19):4839. doi: 10.3390/cancers15194839.
The theranostic approach in oncology holds significant importance in personalized medicine and stands as an exciting field of molecular medicine. Significant achievements have been made in this field in recent decades, particularly in treating neuroendocrine tumors using 177-Lu-radiolabeled somatostatin analogs and, more recently, in addressing prostate cancer through prostate-specific-membrane-antigen targeted radionuclide therapy. The promising clinical results obtained in these indications paved the way for the further development of this approach. With the continuous discovery of new molecular players in tumorigenesis, the development of novel radiopharmaceuticals, and the potential combination of theranostics agents with immunotherapy, nuclear medicine is poised for significant advancements. The strategy of theranostics in oncology can be categorized into (1) repurposing nuclear medicine agents for other indications, (2) improving existing radiopharmaceuticals, and (3) developing new theranostics agents for tumor-specific antigens. In this review, we provide an overview of theranostic development and shed light on its potential integration into combined treatment strategies.
肿瘤诊疗一体化方法在个性化医疗中具有重要意义，是分子医学中一个令人兴奋的领域。近几十年来，该领域取得了重大进展，特别是在使用177-Lu放射性标记的生长抑素类似物治疗神经内分泌肿瘤方面，以及最近在通过前列腺特异性膜抗原靶向放射性核素治疗来治疗前列腺癌方面。在这些适应症中获得的有前景的临床结果为该方法的进一步发展铺平了道路。随着肿瘤发生过程中新分子参与者的不断发现、新型放射性药物的开发以及诊疗一体化药物与免疫疗法的潜在联合，核医学有望取得重大进展。肿瘤诊疗一体化策略可分为：（1）将核医学药物用于其他适应症；（2）改进现有放射性药物；（3）开发针对肿瘤特异性抗原的新型诊疗一体化药物。在本综述中，我们概述了诊疗一体化的发展，并阐明了其融入联合治疗策略的潜力。
